<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861965</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-001-HM</org_study_id>
    <nct_id>NCT00861965</nct_id>
  </id_info>
  <brief_title>Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers</brief_title>
  <official_title>A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStimTM) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovative Therapies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunovative Therapies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II clinical investigation is designed to determine the safety and anti-tumor&#xD;
      effects of intravenous administration of the experimental immunotherapy drug, called&#xD;
      AlloStim. The active ingredient of AlloStim is living, human immune cells that have been&#xD;
      differentiated and expanded outside the body. Because AlloStim does not require HLA match, it&#xD;
      is being evaluated as an alternative to allogeneic bone marrow/stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AlloStim is being tested to determine if it might elicit the same anti-tumor mechanism that&#xD;
      occurs in allogeneic bone marrow/stem cell transplant (BMT) procedures, without the toxicity&#xD;
      associated with graft vs. host disease (GVHD). In allogeneic BMT settings, patients are first&#xD;
      conditioned to weaken the immune system in order to enable the engraftment of allogeneic&#xD;
      donor cells. Patients require a matched-tissue donor in this setting in order to enable&#xD;
      engraftment and also to minimize GVHD toxicity. While allogeneic BMT is a potentially curatve&#xD;
      therapy, the treatment-related mortality, mostly related to GVHD toxicity, is high. This&#xD;
      toxicity limits the clinical utility of this procedure. AlloStim is being tested to determine&#xD;
      if it might be a less toxic alternative to allogeneic BMT.&#xD;
&#xD;
      In this protocol, patients are not conditioned with chemotherapy prior to treatment.&#xD;
      Therefore, the allogeneic cells in AlloStim are expected to be rejected by the patient's&#xD;
      immune system within 24-48 hours of infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    withdrawn due to poor recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of administration of an intravenous AlloStim-9 infusion and to define any drug-related toxicity and reversibility of such toxicity</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>evaluate the safety of administration of up to three consecutive daily intravenous AlloStim-8 booster infusions in patients that previously received a infusion of AlloStim-9 and to define any drug-related toxicity and reversibility of such toxicity</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the anti-tumor effect of AlloStim infusions by evaluating the objective response rates</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AlloStim-8</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim-8</intervention_name>
    <description>intravenous infusion of mis-matched AlloStim-8</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim-8</intervention_name>
    <description>intravenous infusion of AlloStim-8 on day 7</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim-8</intervention_name>
    <description>intravenous infusion of AlloStim-8 on day 14</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim-8</intervention_name>
    <description>intravenous infusion of AlloStim-8 on day 21</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed hematological malignancy of 1 of the following types:&#xD;
&#xD;
               -  Acute Myeloid Leukemia (AML) meeting the following criteria:&#xD;
&#xD;
                    -  Relapsed or primary refractory disease with ≤ 10% blasts in the peripheral&#xD;
                       blood and ≤ 20% blasts in the bone marrow.&#xD;
&#xD;
               -  Acute Lymphoblastic Leukemia (ALL) meeting the following criteria:&#xD;
&#xD;
                    -  Relapsed or primarily refractory disease with ≤ 10% blasts in the peripheral&#xD;
                       blood and ≤ 20% blasts in the bone marrow&#xD;
&#xD;
               -  Chronic Myeloid Leukemia (CML)* with an inadequate response to imatinib meeting 1&#xD;
                  of the following criteria:&#xD;
&#xD;
                    -  Second or subsequent chronic phase&#xD;
&#xD;
                    -  Accelerated phase [*Patients with CML in blast crisis (&gt; 30% promyelocytes&#xD;
                       and myeloblasts in the bone marrow) are not eligible]&#xD;
&#xD;
               -  Non-Hodgkin's Lymphoma (NHL) including Mantle Cell Lymphoma (MCL) meeting 1 of&#xD;
                  the following criteria:&#xD;
&#xD;
                    -  Primary refractory disease or in refractory relapse&#xD;
&#xD;
                    -  Relapsed disease after autologous stem cell transplantation&#xD;
&#xD;
                    -  Chemosensitive relapsed disease without CR to standard salvage therapy AND&#xD;
                       no option for autologous stem cell transplantation due to blood or marrow&#xD;
                       involvement or failure to harvest sufficient autologous stem cells.&#xD;
&#xD;
               -  Chronic Lymphocytic Leukemia (CLL) meeting both of the following criteria:&#xD;
&#xD;
                    -  Stage III or IV disease&#xD;
&#xD;
                    -  Refractory to fludarabine, Rituxan® and Campath® or refuses&#xD;
&#xD;
               -  Multiple Myeloma (MM) meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Primary refractory disease or in refractory relapse&#xD;
&#xD;
                    -  Relapsed disease after autologous stem cell transplantation&#xD;
&#xD;
               -  Hodgkin's Disease&#xD;
&#xD;
                    -  Relapsed after prior autologous transplant or after 2 or more combination&#xD;
                       chemotherapy regimens and ineligible for autologous stem cell transplant.&#xD;
&#xD;
               -  EBV driven lymphoproliferative disorders in immunocompetent patients progressing&#xD;
                  despite standard therapies, including:&#xD;
&#xD;
                    -  T-cell Non-Hodgkin's Lymphoma&#xD;
&#xD;
                    -  Burkitt's Lymphoma&#xD;
&#xD;
                    -  EBV+ Hodgkin's Disease&#xD;
&#xD;
                         -  Ability to comprehend the investigational nature of the study and&#xD;
                            provide informed consent.&#xD;
&#xD;
                         -  Measurable or evaluable disease&#xD;
&#xD;
                         -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt;2.&#xD;
&#xD;
                         -  Age 18 years or older&#xD;
&#xD;
                         -  Expected survival 6 months or longer&#xD;
&#xD;
                         -  No radiation or chemotherapy in previous 2 weeks&#xD;
&#xD;
                         -  No immunotherapy in the previous 4 weeks&#xD;
&#xD;
                         -  Absence of active infection within 2 weeks&#xD;
&#xD;
                         -  Adequate hepatic function, with total bilirubin level less than 1.2&#xD;
                            times the upper limit of normal (ULN) and aspartate and alanine&#xD;
                            aminotransferase levels less than 2.5 times the ULN prior to infusion&#xD;
&#xD;
                         -  Adequate bone marrow function defined as a white blood cell count of at&#xD;
                            least 2 x 109/L (2000/µL), absolute neutrophil count of at least 1 x&#xD;
                            109/L (1000/µL), hemoglobin level of at least 80 g/L (8.0 g/dL), and a&#xD;
                            platelet count of at least 50 x 109/L (50,000/µL) priot to infusion.&#xD;
                            Patients who are transfusion- or growth factor-dependent are allowed,&#xD;
                            provided these values could be achieved with transfusion.&#xD;
&#xD;
                         -  Adequate cardiovascular function defined as no ischemia, no new&#xD;
                            conduction system abnormalities, no class 3 or 4 New York Heart&#xD;
                            Association congestive heart failure, and no myocardial infarction in&#xD;
                            the previous 6 months. A ≥45% left ventricular ejection fraction (LVEF)&#xD;
                            required in the previous 6 months.&#xD;
&#xD;
                         -  Adequate kidney function defined as serum creatinine level 1.5 mg/dL or&#xD;
                            less, or an estimated creatinine clearance level of at least 60 mL/min&#xD;
                            prior to infusion.&#xD;
&#xD;
                         -  Adequate lung function defined as pulse oxymetry greater than or equal&#xD;
                            to 92% on room air prior to infusion, DLco≥50%, FEV1 and FVC ≥50%&#xD;
                            within 2 weeks&#xD;
&#xD;
                         -  No known allergy to murine products or HAMA testing results within&#xD;
                            normal limits&#xD;
&#xD;
                         -  No known allergy to bovine products&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No pregnancy or breast feeding&#xD;
&#xD;
          -  No known human immunodeficiency virus (HIV+)&#xD;
&#xD;
          -  No seropositivity or active viral hepatitis (HBV+, HCV+)&#xD;
&#xD;
          -  No prior allogeneic transplant (cell or organ)&#xD;
&#xD;
          -  No serious concomitant medical or psychiatric conditions that could interfere with&#xD;
             treatment.&#xD;
&#xD;
          -  No EBV-induced lymphomas associated with immunosuppression, including patients with&#xD;
             iatrogenic immunodeficiencies (such as organ transplant) or HIV-related&#xD;
             immunodefiency.&#xD;
&#xD;
          -  No chronic myelogenous leukemia in blast crisis.&#xD;
&#xD;
          -  No myelodysplastic syndromes with refractory anemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Michael Har-Noy</last_name>
    <role>Study Director</role>
    <affiliation>Immunovative Therapies, Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunotherapy Clinical Associates, PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Immunovative Clinical Research, Inc</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.</citation>
    <PMID>18834631</PMID>
  </reference>
  <reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Slavin S. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.</citation>
    <PMID>18565579</PMID>
  </reference>
  <reference>
    <citation>Har-Noy M, Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Med Hypotheses. 2008;70(6):1186-92. Epub 2007 Dec 3.</citation>
    <PMID>18054441</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

